ResearcherHarvard UniversityActive in the last 2 years
Eunjung Lee
Matched on ORCID iD 0000-0002-8287-6131; OpenAlex author ID A5100398838. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 25
2013: 1 paper · 2014: none · 2015: 1 paper · 2016: none · 2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: none · 2022: none · 2023: 1 paper · 2024: 2 papers
Papers 6
- Whole-genome bisulfite sequencing identifies stage- and subtype-specific DNA methylation signatures in pancreatic cancer. Co-author DOI 10.1016/j.isci.2024.109414↗
- Familial Pancreatic Cancer Research: Bridging Gaps in Basic Research and Clinical Application. Co-author DOI 10.3390/biom14111381↗
- A new vulnerability to BET inhibition due to enhanced autophagy in BRCA2 deficient pancreatic cancer. Co-author DOI 10.1038/s41419-023-06145-9↗
- Large-scale clinical validation of biomarkers for pancreatic cancer using a mass spectrometry-based proteomics approach. First author DOI 10.18632/oncotarget.17463↗
- The retinoic acid derivative, ABPN, inhibits pancreatic cancer through induction of Nrdp1. Co-author DOI 10.1093/carcin/bgv148↗
- Reproductive factors, exogenous hormones, and pancreatic cancer risk in the CTS. Co-author DOI 10.1093/aje/kwt154↗
Closest collaborators
The 25 strongest of 25 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Chang‐Il Hwang · 3 shared papers, 2023–2024 · strength 0.65
- Paper Familial Pancreatic Cancer Research: Bridging Gaps in Basic Research and Clinical Application. DOI 10.3390/biom14111381↗
- Paper Whole-genome bisulfite sequencing identifies stage- and subtype-specific DNA methylation signatures in pancreatic cance… DOI 10.1016/j.isci.2024.109414↗
- Paper A new vulnerability to BET inhibition due to enhanced autophagy in BRCA2 deficient pancreatic cancer. DOI 10.1038/s41419-023-06145-9↗
- Suyakarn Archasappawat · 2 shared papers, 2023–2024 · strength 0.44
- Peinan Liu · 1 shared paper, 2024 · strength 0.28
- Sarah S. Wang · 1 shared paper, 2024 · strength 0.21
- Ja‐Lok Ku · 1 shared paper, 2024 · strength 0.21
- Soon‐Chan Kim · 1 shared paper, 2024 · strength 0.21
- Richard J. Bold · 1 shared paper, 2024 · strength 0.21
- Sang Hyub Lee · 1 shared paper, 2024 · strength 0.21
- Jin‐Young Jang · 1 shared paper, 2024 · strength 0.21
- Timothy Spicer · 1 shared paper, 2023 · strength 0.16
- Virneliz Fernández-Vega · 1 shared paper, 2023 · strength 0.16
- Joon-Oh Park · 1 shared paper, 2017 · strength 0.06
- Jin Seok Heo · 1 shared paper, 2017 · strength 0.06
- Soo‐Youn Lee · 1 shared paper, 2017 · strength 0.06
- Kee‐Taek Jang · 1 shared paper, 2017 · strength 0.06
- Young Suk Park · 1 shared paper, 2017 · strength 0.06
- Dong Wook Choi · 1 shared paper, 2017 · strength 0.06
- Jong Kyun Lee · 1 shared paper, 2017 · strength 0.06
- Jisook Park · 1 shared paper, 2017 · strength 0.06
- Seong Ho Choi · 1 shared paper, 2017 · strength 0.06
- Hyung‐Doo Park · 1 shared paper, 2017 · strength 0.06
- Kwang Hyuck Lee · 1 shared paper, 2017 · strength 0.06
- Zigang Dong · 1 shared paper, 2015 · strength 0.04
- Sanguine Byun · 1 shared paper, 2015 · strength 0.04
- Leslie Bernstein · 1 shared paper, 2013 · strength 0.04
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.